On December 10, 2025, Oddo BHF initiated coverage on Alcon (NYSE:ALC) with a bullish outlook, assigning it an "Outperform" grade. At the time, the stock price was $79.66. Alcon is a leading Swiss eyecare company, known for its innovative products and services in the healthcare sector. It competes with other major players in the eyecare and medical technology industries.
Alcon's recent strategic move involves increasing its offer to acquire Staar Surgical, a medical technology firm, to $30.75 per share in cash. This new bid values Staar at $1.6 billion, as highlighted by Reuters. This acquisition is part of Alcon's growth strategy, aiming to strengthen its market position and expand its product offerings in the eyecare sector.
The stock for ALC is currently priced at $79.69, reflecting an increase of $1.02, or 1.30% in percentage terms. Today, the stock has fluctuated between a low of $78.91 and a high of $79.80. Over the past year, ALC has reached a high of $99.20 and a low of $71.55. This volatility indicates investor interest and market reactions to Alcon's strategic decisions.
Alcon's market capitalization stands at approximately $39.41 billion, reflecting its significant presence in the healthcare industry. The company's recent announcement of an amended merger agreement with STAAR Surgical, as reported by Business Wire, marks a significant step in their collaboration. This development could potentially impact their market positions and future growth strategies.
Today's trading volume for ALC is 975,777 shares on the NYSE, indicating active investor engagement. Alcon's strategic moves, such as the acquisition of Staar Surgical, are likely to influence its stock performance and market perception. Investors and analysts will be closely monitoring Alcon's progress and its impact on the eyecare industry.
